Effect of Ile-Pro-Pro (IPP) on Endothelial Function in Patients With Coronary Artery Disease

Completed · Not applicable · Has a placebo group

Conditions studied: Coronary Artery Disease

In brief

This study will investigate whether the lacto-tripeptide Ile-Pro-Pro (IPP) improves the function of the endothelium in patients with coronary artery disease. The study has a crossover design. Participants will be treated with a protein hydrolysate rich in IPP for 12 weeks and placebo for 12 weeks with a four-week rest period between treatment periods. The investigators will use ultrasound to test the function of the endothelium in the brachial artery before, after 6 weeks, and after 12 weeks of each treatment. Blood will be collected before and after each treatment. The investigators hypothesize that IPP will improve endothelial function.

Key facts

Study ID

NCT00924157

Run by

Boston University

People needed

54

Starts

2009-07-01

Expected to finish

2012-05-01

Last updated by the study team

2012-05-25

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Coronary artery disease

You may not qualify if…

• Treatment with an ACE inhibitor or ARB
• Pregnancy
• Other major illness
• Treatment with an investigational drug within 4 weeks

Where it is running

• Boston University Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.